Case Name (Date)

Faulkner et al. v. Acella Pharmaceuticals, LLC
22-cv-92, N.D. Ga.
(May 2022)


Product/Service

NP Thyroid


Allegations

Falsely marketing that medications contain a specific amount of the active ingredient when certain batches were recalled for containing too much or too little of the active ingredient

Falsely marketing medications as safe when certain batches were recalled because the amount of the active ingredient could cause serious adverse health consequences or death

Falsely marketing that medications are “[m]ade with the highest quality standards” and comply with applicable USP standards


Status

Settled
(Final approval granted)

https://nptsettlement.com/



The Latest

Filters

Stellantis Steers Away from Deceptive Made in USA Claims

Press Release

Stellantis Steers Away from Deceptive Made in USA Claims

MADISON, CONN. April 9, 2025 — Dutch automaker Stellantis has paused its new “American Born” campaign after getting called out by consumer advocacy organization truthinadvertising.org (TINA.org). Released in the wake…


Show More